Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03185897 · ClinicalTrials.gov registry record
Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia
A clinical trial, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- 242
- Enrollment target
NCT03185897: Completed study, sponsored by Baxalta now part of Shire.
NCT03185897 is a clinical trial that has completed, run by Baxalta now part of Shire. The registered enrollment target is 242 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03185897 has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- 242 participants
- Enrollment target
Study Summary
Assess the seroprevalence of neutralizing antibodies (NAb) to AAV in adults with severe hemophilia A (coagulation factor VIII \[FVIII\] \<1%) or moderately severe to severe hemophilia B (coagulation factor IX \[FIX\] ≤2%).
Primary Outcome
Prevalence of NAb to naturally occurring adeno-associated virus (AAV) serotypes
Interventions
- OTHER Non-treatment, seroprevalence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2017-06-14 |
| Est. Completion | 2021-03-17 |
What the finished NCT03185897 record still lists
NCT03185897 is an observational study that tracks outcomes without assigning an intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Non-treatment, seroprevalence is the first listed.
NCT03185897 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03185897 about?
NCT03185897 is a clinical study titled "Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia". Assess the seroprevalence of neutralizing antibodies (NAb) to AAV in adults with severe hemophilia A (coagulation factor VIII \[FVIII\] \<1%) or moderately severe to severe hemophilia B (coagulation factor IX \[FIX\] ≤2%).
What is the current status of trial NCT03185897?
This trial is currently completed. The enrollment target is 242 participants. The study started on 2017-06-14. Estimated completion is 2021-03-17.
What interventions are being tested in trial NCT03185897?
The interventions under investigation include: Non-treatment, seroprevalence (OTHER).
Who is sponsoring clinical trial NCT03185897?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI